// App-Quantinova.ai

SAT0503 : SERIOUS INFECTION RISK IN PEDIATRIC PATIENTS WITH LOW IMMUNOGLOBULIN LEVELS FOLLOWING RITUXIMAB TREATMENT FOR GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA)

Researchers

Presenter

  • S. Melega

Principal Investigators

  • P. Brogan

  • G. Cleary

  • A. Hersh

  • O. Kasapcopur

  • S. Rangaraj

  • R. Yeung

  • A. Zeft

  • J. Cooper

  • P. Pordeli

  • P. Kirchner

  • P. Lehane

Medical Centers

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Dubowitz Neuromuscular Centre, Institute of Child Health and Great Ormond Street Hospital, London, United Kingdom

  • Microbiology, Alder Hey Childrens Hospital, Liverpool, United Kingdom

  • University of Utah Primary Children’s Hospital, Salt Lake City, United States of America

  • Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

  • Cleveland Clinic, Cleveland, OH, United States of America

  • Children’s Hospital Colorado - Aurora - United States of America

  • Roche Products Ltd, Mississauga, Canada

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

Locations

  • Switzerland

  • United Kingdom

  • United States

  • Turkey

  • Canada

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Wegener's granulomatosis

  • Microscopic polyangiitis

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • Glucocorticoid

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Roche Holding AG

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved